(June. 2022 standard)
Classification | Project Name | Treatment for | Discovery | Pre-clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|---|---|---|
IMD | BR1015 | Hypertension | |||||
BR1017 | Hypertension | ||||||
BR1018 | Hypertension |
Pipeline
The Research Team at Boryung aims to lead the Future of the Pharmaceutical Industry
Pipeline Introduction
After 12 years of research, Boryung succeeded in developing the first domestic hypertension drug, ‘Kanarb’. By independently carrying out all the necessary steps – candidate material excavation, raw material synthesis, formulation research, a non-clinical trial, and clinical trial phases one, two and three – Boryung has established our very own capability for drug development. Boryung was established based on its drug development capabilities. We are expanding our scope of research into a variety of areas to develop drugs for cancer treatment, antibiotics, NCE(New Chemical Entity) and gene therapy that focuses on cardiovascular and other major diseases, vaccines and other biopharmaceuticals. We are particularly focused on the development of the Kanarb Value-Up Pipeline. In addition, we are focusing on the research and development of new API(Active Pharmaceutical Ingredient) products aimed at the globalization of API.
Kanarb Value-up Pipeline
The ‘Kanarb Value-up Pipeline’ consists of products that allow for the integrative treatment of patients with hypertension associated with the majority of metabolic diseases. These products are all NCE and IMDs and developed in-house.
Development of the ‘Kanarb Value-up Pipeline’ will not only increase sales in the single and composite drug market, but will also strengthen the global competitiveness of Kanarb through the global license out.
(June. 2022 standard)
Classification | Project Name | Treatment for | Discovery | Pre-clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|---|---|---|
IMD | BR1015 | Hypertension | |||||
BR1017 | Hypertension | ||||||
BR1018 | Hypertension |
Kanarb Value-up Pipeline
(June. 2022 standard)
IMD | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
BR1015 Hypertension
|
||||||||||
BR1017 Hypertension
|
||||||||||
BR1018 Hypertension
|
Pipeline
We are strengthening our R&D portfolio to focus on antibiotics and major diseases such as cancer and cardiovascular disease (CV). We will add a new pipeline that centers on diseases whose markets are expected to grow in the future. We are also focusing on developing NCE and incrementally modified drugs (IMD) to fulfill unmet needs, while working to discover new drugs on the cutting edge of bio-tech.
(Ju. 2022 standard)
sification | Project Name | Treatment for | Discovery | Pre-clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|---|---|---|
NCE | BR2002 | Cancer | |||||
BR2010 | Cancer | ||||||
BR2011 | Cancer | ||||||
NCE(external) | Lurbinectedin | Cancer | |||||
Plitidepsin | Cancer | ||||||
PeproStat | Haemostasis | ||||||
ReadyFlow | Haemostasis | ||||||
IMD | BR4002 | Alzheheimer's disease | |||||
BR2008 | Cancer | ||||||
BR2009 | Cancer | ||||||
BR3003 | Diabetes |
Pipeline
(June. 2022 standard)
NCE | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
BR2002 Cancer
|
||||||||||
BR2010 Cancer
|
||||||||||
BR2011 Cancer
|
||||||||||
NCE(external) | ||||||||||
Lurbinectedin Cancer
|
||||||||||
Plitidepsin Cancer
|
||||||||||
PeproStat Haemostasis
|
||||||||||
ReadyFlow Haemostasis
|
||||||||||
IMD | ||||||||||
BR4002 Alzheimer’s disease
|
||||||||||
BR2008 Cancer
|
||||||||||
BR2009 Cancer
|
||||||||||
BR3003 Diabetes
|
136, Changgyeonggung-ro, Jongno-gu, Seoul, Republic of Korea (03127)
Copyright (C) 2022 by Boryung Pharmaceutical Co.,Ltd. All Rights Reserved.